文献速递泌尿男性生殖肿瘤

原发前列腺癌与转移灶或游离DNA中DNA修复基因突变的一致性

Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.
PubMed 文献 · JAMA Oncol · 2021-06-04

该研究纳入72例已知DDR通路突变且原发组织可测序的前列腺癌患者,比较原发组织与转移组织或ctDNA的突变一致性。排除仅CHIP/胚系事件后51例可分析,原发与转移或ctDNA的DDR突变一致率为84%(95%CI 71%-92%),提示多数DDR突变为主干事件,原发组织可反映可靶向突变状态。

要点

  • 原发前列腺组织与转移灶或ctDNA的DDR基因突变一致率达84%。
  • 排除CHIP后ctDNA可准确捕获DDR突变并检出耐药相关回复突变。
  • 原发组织测序或可替代转移灶活检指导DDR靶向治疗。

核心结论

  • 原发前列腺组织能准确反映转移组织中可靶向DDR基因的突变状态,符合多数DDR突变为肿瘤主干事件的假设。
  • 排除可能的CHIP事件后,ctDNA分析可准确捕获这些DDR突变,并能检出提示耐药机制的回复突变。

研究设计与样本

  • 遗传关联研究,分析3个队列:FoundationOne、华盛顿大学临床病例(UW-OncoPlex或SU2C-PCF国际梦想团队测序流程)和华盛顿大学快速尸检系列。
  • 纳入标准为转移组织或ctDNA检出DDR通路突变且原发组织测序可比较,仅纳入致病性体细胞突变,原发组织与ctDNA和/或转移组织采集间隔需超过30天。
  • 共72例已知DDR突变的男性纳入分析,排除ctDNA仅见CHIP和/或胚系事件者21例后,最终分析51例。
  • 原发组织采集至ctDNA或肿瘤组织采集的中位(范围)时间为55(5-193)个月。

主要发现

  • 样本间DDR基因突变状态的一致率为84%(95%CI 71%-92%)。
  • 排除CHIP事件后,转移-原发与ctDNA-原发配对的一致性率相似。
  • 2例患者ctDNA中检出与PARP抑制剂和铂类化疗耐药相关的多克隆BRCA2回复突变。

临床怎么用

  • 对于无法获取转移灶活检的晚期前列腺癌患者,可考虑用原发组织测序评估可靶向DDR基因突变。
  • 排除CHIP事件后,ctDNA可替代转移组织用于DDR突变检测,并可检出回复突变提示耐药。

局限性

  • 最终分析样本量较小(51例)。
  • 原发组织与转移灶或ctDNA采集间隔中位达55个月,时间跨度较大。
  • 仅纳入致病性体细胞突变,CHIP和胚系事件由专家病理学家裁定排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: DNA damage repair (DDR) gene mutations represent actionable alterations that can guide precision medicine strategies for advanced prostate cancer. However, acquisition of contemporary tissue samples for molecular testing can be a barrier to deploying precision medicine approaches. We hypothesized that most DDR alterations represent truncal events in prostate cancer and that primary tissue would faithfully reflect mutations found in cell-free circulating tumor DNA (ctDNA) and/or metastatic tissue. OBJECTIVE: To assess concordance in DDR gene alterations between primary prostate cancer and metastases or ctDNA specimens. DESIGN, SETTING, AND PARTICIPANTS: Patients were included if a DDR pathway mutation was detected in metastatic tissue or ctDNA and primary tissue sequencing was available for comparison. Sequencing data from 3 cohorts were analyzed: (1) FoundationOne, (2) University of Washington clinical cases (University of Washington-OncoPlex or Stand Up to Cancer-Prostate Cancer Foundation International Dream Team sequencing pipelines), and (3) University of Washington rapid autopsy series. Only pathogenic somatic mutations were included, and more than 30 days between primary tumor tissue and ctDNA and/or metastatic tissue acquisition was required. Clonal hematopoiesis of indeterminate potential (CHIP) and germline events were adjudicated by an expert molecular pathologist and excluded. MAIN OUTCOMES AND MEASURES: The DDR gene alterations detected in primary prostate tissue matched with metastatic tissue and/or ctDNA findings. RESULTS: A total of 72 men with known DDR alterations were included in the analysis, and primary samples with paired ctDNA and/or metastatic tissue were sequenced. After excluding patients with ctDNA where only CHIP and/or germline events (n = 21) were observed, 51 patients remained and were included in the final analysis. The median (range) time from acquisition of primary tissue to acquisition of ctDNA or tumor tissue was 55 (5-193) months. Concordance in DDR gene mutation status across samples was 84% (95% CI, 71%-92%). Rates of concordance between metastatic-primary and ctDNA-primary pairs were similar when patients with CHIP events were excluded. Multiclonal BRCA2 reversion mutations associated with resistance to PARP inhibitors and platinum chemotherapy were detected in ctDNA from 2 patients. CONCLUSIONS AND RELEVANCE: In this genetic association study of 3 patient cohorts, primary prostate tissue accurately reflected the mutational status of actionable DDR genes in metastatic tissue, consistent with DDR alterations being truncal in most patients. After excluding likely CHIP events, ctDNA profiling accurately captured these DDR mutations while also detecting reversion alterations that may suggest resistance mechanisms.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Schweizer MT, Sivakumar S, Tukachinsky H, et al. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. JAMA Oncol. 2021. PMID: 34086042. doi:10.1001/jamaoncol.2021.2350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。